# Egle Therapeutics

Source: https://onco.cc/companies/egle-therapeutics/  
OnCo record `egle-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Egle Therapeutics is a Paris company developing medicines that act on regulatory T cells, the immune cells that can shield a tumour from attack. Its cancer drug, EGL-001, is designed to selectively inhibit these cells inside tumours and is in an early trial in advanced solid tumours.

## Summary

Egle Therapeutics SAS, based in Paris, develops IL-2 variant immunoconjugates that modulate regulatory T cells (Tregs), using a proprietary discovery platform to find Treg-specific targets. In oncology its lead candidate EGL-001 is a Treg-selective anti-CTLA-4 antibody fused to a modified IL-2 (anti-CTLA4-IL-2m), designed to selectively inhibit Tregs in tumours; in autoimmunity EGL-003 is an IL-2 agonist Treg engager. Christophe Queva was appointed chief executive in January 2025, and the website now names John Celebi as chief executive. Its first registered cancer trial, NCT06622486, a first-in-human phase 1/2 study of EGL-001 in selected advanced or metastatic solid tumours at sites in France and Spain, was posted on ClinicalTrials.gov in October 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Egle Therapeutics SAS
- HQ: Paris
- Type: biotech
- Website: https://www.egle-tx.com/

## Notes

- Founding year not stated in the pages read. No financing round is recorded because no primary source for one was read; the website says only that it is backed by prominent investors. Read on 29 October 2026.

## Sources

- Official website: https://www.egle-tx.com/
- Chief executive appointment, January 2025: https://www.egle-tx.com/egle-therapeutics-strengthens-its-executive-leadership-team-with-the-appointment-of-christophe-queva-ph-d-as-chief-executive-officer/
- ClinicalTrials.gov: phase 1/2 trial of EGL-001 (NCT06622486): https://clinicaltrials.gov/study/NCT06622486

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Immunocytokines (antibody-cytokine fusions)](https://onco.cc/technologies/immunocytokines/)
- targets: [CTLA-4](https://onco.cc/targets/ctla4/)
- trials: [First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors](https://onco.cc/trials/nct06622486/)

---
JSON: https://onco.cc/api/v1/entities/egle-therapeutics.json